Larval therapy has been reported to exert beneficial actions upon chronic wound healing by promoting granulation tissue formation, antimicrobial activity and degrading necrotic tissue. However, the use of live maggots is problematic for patient acceptance, and thus there is a need to develop materials which can adsorb and release therapeutic biomolecules from maggot secretions. Here we describe the fabrication of a novel bioactive scaffold that can be loaded with Lucilia sericata maggot excretion/secretion (L. sericata maggot E/S) for wound therapy, and which also provides structural stability for mammalian cell-growth and migration. We show that electrospun scaffolds can be prepared from polycaprolactone-poly (ethylene glycol)-block copolymer (PCL-b-PEG) blended with PCL, to form fibres with average diameters of ~4 μm. We further demonstrate that the fibres are able to be loaded with L. sericata maggot E/S, in order to influence fibroblast migration through protease activity. Finally, we show that after 21 days, the cumulative amount of released L. sericata maggot E/S was ~14 μg/mL from PCLb-PEG/PCL scaffolds and that the protease activity of L. sericata maggot E/S was preserved when PCL-b-PEG/PCL scaffolds were used as the release platform.
Introduction
Larval therapy has been reported to exert beneficial actions upon chronic wound healing [1, 2] . The alimentary fluid from Lucilia sericata excretion/secretion (L. sericata maggot E/S) contains a range of serine proteinases, which can degrade necrotic tissue [3] , disinfect the wound sites [4] and promote granulation tissue formation at the wound site [5] . The beneficial effect of larval excretion/secretion on wound healing is strongly supported by 8 clinical trials [6] [7] [8] , supported by in vitro studies [9] . The FDA (Food and Drug Administration, USA) approved L. sericata maggot E/S therapy as a medical device in January 2004 [10] . In the same year, the National Health Service in the UK approved the prescription of sterile L. sericata maggot for debridement therapy [7] . However, there are many limitations of the use of sterile L. sericata maggots for wound healing. These include i) maggots require a moist environment to survive, for this reason the use of L. sericata maggots is accepted exclusively for treatment of exudative wounds and contraindicated on dry wounds ii) maggots produce malodour and discomfort to the patient and iii) even though they are only used when located within a porous bag, there is poor acceptance by patients and by medical staff [11] . For this reason, research groups have tried to incorporate the active molecules from L. sericata maggot E/S in pharmaceutical formulations. Prototype hydrogels containing recombinant L. sericata chymotrypsin have been developed and were shown to accelerate wound closure ex vivo [12] . In addition, L. sericata maggot E/S has been incorporated and released in a PVA hydrogel. Findings showed a significant enhancement on the rate of wound closure (in vitro scratch assay) when the wounds were exposed to L. sericata maggot E/S released from the hydrogel compared with control [13] . However, hydrogel formulations have 90 % water content and are their used can result in skin maceration and bacterial colonization if wounds for treatment are highly exudative and this in turn can delay/impair the wound closure [14] .
Accordingly, there is a need for more robust, non-hydrogel, formulations L. sericata maggot E/S which could be used to support fibroblast proliferation and migration in accelerated wound healing applications.
Electrospun scaffolds provide a potential means to meet this need, as they have solid, fibrous and porous structures that can serve as a substitute for the native extracellular matrix [4] . Electrospinning is a versatile technique that allows the fabrication of nano-and micro-fibres by modifying the process parameters [5] . Many synthetic polymers have been used to generate fibrous scaffolds though electrospinning of which the most widely-applied in medical applications are those on poly(lactic acid) (PLA) and polycaprolactone (PCL), either as homopolymers or as blends with poly (ethylene glycol) (PEG) [6] . This is because PLA and PCL have been authorised for clinical application in drug delivery devices [7] , while Poly (ethylene glycol) (PEG) is component of many existing medical and consumer products. These synthetic polymers are advantageous for clinical purposes as they are relatively cheap compared to highly purified natural polymers, and synthetic materials can be more easily tuned to enhance specific properties such as mechanical strength, shape and biodegradation rate [8] . Fibrous scaffolds derived from these polymers can be further enhanced to be bioactive through the incorporation of therapeutic agents which can then be released as the fibres swell or degrade in biological media. Bioactive fibrous scaffolds refer to a matrix or scaffold that provide structural support for cells and with the intention of guiding the cellular response by delivering therapeutic molecules [10] . Bioactive electrospun scaffolds have been used in areas such as cancer treatment for the release of doxorubicin, and in cardiovascular disease to release bioactive agents (i.e growth factors, heparin, anti-inflammatories) [11] . In wound healing, the most common loaded drugs are antibiotic [12] , herbal extracts [13] and proteins (i.e growth factors) [14] . Furthermore, while some synthetic polymers can present challenges with respect to biocompatibility due to the lack of specific cell-recognition motifs and suboptimal cell-surface interfacial interactions, [9] they can be surface-modified post-spinning with appropriate functionalities if required to encourage cell attachment and growth [15] .
Here, we describe an approach to bioactive scaffolds designed to allow the sustainable release of L. sericata maggot E/S from the electrospun fibres as well as support for cell proliferation and migration. polycaprolactonepoly (ethylene glycol)-block copolymer (PCL-b-PEG) blended with PCL (PCL-PEG/PCL) was electrospun to create the fibrous scaffold, with PEG included within the scaffolds to enhance the wettability and cytocompatibility of the surface, and to accelerate the degradation rate of the polymer, and thereby improve L.
sericata maggot E/S release. To test these hypotheses, the in vitro biocompatibility and migratory behaviour of 3T3 GFP mouse dermal fibroblasts and human BJ6 fibroblasts, on electrospun PCL and PCL-b-PEG/PCL scaffolds were investigated.
L. sericata maggot E/S was incorporated in the scaffolds by post electrospinning modification. Release evaluation was carried out by immersing the loaded-scaffolds in PBS for 21 days. And the relative bioactivity of L. sericata maggot E/S was confirmed by examining protease activity after the release.
We believe these data demonstrate that effective biomaterial can be produced by electrospinning, that it can incorporate and release L. sericata maggot E/S bioactive molecules, and that the fibrous scaffolds can enhance cellular infiltration and proliferation
Materials and Methods

Development of electrospun scaffolds
Electrospinning electrospun scaffolds were fabricated in a commercial electrospinning apparatus EC-CLI (IME Technologies). PCL scaffold: scaffolds were electrospun using PCL (80 KDa; Sigma Aldrich) dissolved in chloroform (8% w/w) (Life technology, Fisher scientific). PCL scaffolds were used as controls to compare properties with PCL-b-PEG/PCL scaffolds. Monomethoxy poly (ethylene glycol) (mPEG) ( Electrospinning parameters were set as described in complementary data.
Scaffold characterization
Fibre morphology and scaffold thickness
Morphology of the fibres and diameter distribution were evaluated by SEM images, taken with a FEI-XL30 (tungsten filament) scanning electron microscope (Philips). The diameter of individual fibres were measured by using imageJ software (1.48 v, USA National Institutes of Health). A total of five images (at 3000x magnification) from five random fields were used for a total of 100 measurements. For each scaffold, three different samples were taken from top to bottom of the electrospun sheet. Measurement of scaffold thickness were carried out by freezing scaffold samples at -80°C, and after 24 h a cross section of the samples was excised using a cold scalpel blade. Samples were oriented tangentially to the surface of the SEM sample holder and imaged as described above.
For fibre diameter analysis, one hundred measurements were taken using imageJ software. Frequency distribution and non-linear regression (Log Gaussian) was analysed using Prism (GraphPad Prism6, San Diego CA).
Scaffold Porosity
The porosity of the electrospun scaffolds was assessed using micro computed tomography (micro-CT) (Skyscan 1174, Skyscan, Belgium). The samples (in triplicate from 3 different scaffolds) were set vertically inside of a straw and fixed into the top side with blue glue (Blu-tack). The images were binarized with a threshold range 22 to 255 (gray values). A misalignment of -5 to +5 was used. 3-D measurements and structural analysis were performed with CTAn software (Bruker software, SkyScan 1174). NRecon (Bruker software, Skycan 1174) was used to reconstruct 2D slices. In addition, pore size was evaluated.
Water Contact Angle (WCA) Measurements of the WCA at the surface of the electrospun scaffolds were carried out using a modular CAM 200 optical contact angle meter (KSV Instruments Ltd) equipped with a camara (JAi ® ).
Rectangular areas (3x1.5 cm) of the scaffolds PCL and PCL-PEG/PCL (average fibre diameter 4 µm) were fixed to glass cover slips, 3 pieces of the same scaffold were analysed, and measurements repeated 3 times. The sessile drop method, advancing (θa) and receding (θr) analysis were performed (Korhonen et al., 2013).
Mechanical properties/uniaxial tensile properties
Mechanical properties of the electrospun scaffolds were determined with a uniaxial testing machine (TA-HD Plus Texture Analyser, stable Micro System Instron 3345). A 5 Kg load cell under a cross-head speed of 10 mm/min at 25°C was used. All scaffolds were cut in a 'dog bone' shape with dimensions of the rectangle of 15x10 mm.
The thickness were measured with a digital calliper having a precision of 1 µm and confirmed by SEM measurements. At least in triplicate from 3 different scaffolds. Only the scaffolds that had broken in the centre were considered for statistical analysis. Young's modulus, the yield point, the elongation at break and ultimate tensile strength were evaluate and graphs of share rate vs viscosity and shear rate vs shear stress were generated.
In vitro degradation studies
Evaluation of scaffold degradation were carried out using 0.8 mm scaffolds of known weight and immersing them in 5 mL of Phosphate buffer saline (PBS) during agitation at 37°C. Scaffolds were reweighed regularly (0, 1,2,3 and then 5,7,9,11 and 12 months). Additionally, selected samples were taken at time 0, 5 months and 12 months for Gel permeation chromatography (GPC) analysis. One individual experiment in triplicate was carried out.
Biological evaluation of the scaffolds
Mammalian cell maintenance
NIH 3T3, GFP -3T3 mouse embryo fibroblast cells and BJ6 foreskin human fibroblasts cells (passage number 10)
were provided by Dr. James Dixon (The University of Nottingham) and were previously purchased from ECACC. 
Scaffold preparation and cell seeding
To prepare scaffolds for mammalian cell culture, circles of PCL and PCL-PEG/PCL scaffolds, with a diameter of 8 mm were cut from 3 different random areas using a metallic puncher. The scaffolds were fixed to the bottom of a 24 non-tissue culture treated plates with a small quantity of aquarium seal glue. Later, scaffolds were sterilised using a UV lamp (CL-100UV) for 10 min at power 200 (x100 µJ/cm 2 ). Then, scaffolds were immersed in 1 mL of cell culture media and maintained at 37°C, 5% CO2 in air at 95% relative humidity for 24 h. After that, the cell culture media was replaced and scaffolds were seeded with 60,000 cells/well, maintained at 37°C, 5% CO2 in air at 95% relative humidity.
Cell viability
The metabolic activity of NIH 3T3 GFP and BJ6 fibroblasts on each scaffold was determined by performing the 
Cell infiltration into the Scaffolds
Evaluation of the extent of NIH 3T3 GFP infiltration into the scaffolds after 5 days of culture was conducted by z-stacked confocal microscopy (LSCM; Zeiss, LSM880) analysis (pinhole set to 1 Airy unit, pixel dwell time: 0.26 µs, 5 μm plane thickness). Laser excitation at 405 nm and 488 nm were used, and sequential imaging of Hoechst (blue) and GFP (green fluorescent protein) was performed. Experiments were carried out in triplicate from at least three different scaffolds The infiltration depth (%) of the fibroblasts was calculated by estimating the maximum distance (microns) migrated by fibroblasts from the top to the bottom of the scaffolds (visualization on Z-stack) and using the total distance, the thickness of the scaffolds estimated by SEM [16] . detected [20] . Experiments were carried out in triplicate for a minimum of n=3 individual experiments.
Statistical analysis
All data was expressed as mean±SD. Experiments were carried out in triplicate for a minimum of n=3 individual experiments, unless otherwise indicated. To analyse statistically significant differences with respect to cell viability between different scaffolds, protein loading and release from the scaffolds, a Two way-ANOVA with Turkey's multiple comparison post-hoc test was performed using Prism (GraphPad Prism6).
Results
Improved cellular infiltration into scaffolds with PEG content and fibre diameter in a microscale range.
PCL alone and PCL-b-PEG/PCL electrospun fibres were fabricated with an average fibre diameter of ~4 μm. It was hypothesised that the scaffold composed of PCL-b-PEG/PCL fibres may exhibit enhanced wettability and thus enhanced degradation rate and cell-compatibility. Table 1 shows a summary of the scaffold parameters including the static contact angle, advancing and receding water contact angle for scaffolds PCL and PCL-b-PEG/PCL. Contact angle measurements confirmed that only the PCL scaffolds are hydrophobic (108°) whilst the PCL-b-PEG/PCL scaffolds exhibited a water contact angle of 100 o with no statistical significances found. (Table   1 ). In vitro degradation studies were carried out with the PCL scaffold losing 5% of its weight in the first month.
After that, the weight was constant for 7 months with a further weight loss of around 3% and again the weight was maintained. These results were in agreement with GPC analysis of molecular weight and polydispersity which indicated that both scaffolds experienced degradation. (Table 1 ). PCL slightly decreased in molecular weight from 2.9x10 5 to 2.5x10 5 Mw and increased in terms of polydispersity Mw/Mn from 1.2 to 1.4 over 5 months. PCL-b-PEG/PCL scaffolds showed a greater weight loss (around 10%) within the first month. After that, the electrospun scaffolds lost around 20% of their weight in of the following 9-month period. Complementary GPC analysis showed a decrease in molecular weight for the PCL-b-PEG/PCL scaffold from 2.5x10 5 to 1.6x10 5 Mw with an increase in polydispersity Mw/Mn from 1.3 to 2.4 over a period of 5 months. The 3T3 fibroblasts cultured on the PCL-b-PEG/PCL scaffolds proliferated over a 12-day period and showed a significantly higher metabolic activity (p <0.0001) than for those cultured on PCL scaffolds on day 12. No statistically significant differences were found in terms of metabolic activity between fibroblasts cultured on PCLb-PEG/PCL scaffolds and PCL scaffolds during the first 9 days of culture (Figure 2-A) . Figure 2 fibroblasts cultured on PCL scaffolds did not exhibit an increased metabolic activity over 15 days of culture suggesting that they did not proliferate. Metabolic activity on the PCL-b-PEG/PCL scaffolds was significantly higher, illustrating the ability of BJ6 cells to proliferate compared with those cultured on PCL. Figure 3 shows the infiltration of cells cultured on the PCL and PLC-b-PEG/PCL scaffolds, which compares the percentage of fibroblast infiltration with respect to the total thickness of the scaffolds. Fibroblast infiltration on the PCL-b-PEG/PCL scaffold was significantly higher (p≤0.0001) (60%) compared with fibroblast infiltration on the PCL scaffold (40%) (Figure 3-B) . In summary, the highest fibroblast infiltration and highest metabolic activity was seen when cells were cultured on the PCL-b-PEG/PCL scaffolds in comparison to scaffolds fabricated from PCL alone. Three independent experiments carried out in triplicate (means±SD). Ns for P>0.05, * for P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001. reached values of accumulative release of 25% from PCL-b-PEG/PCL scaffolds, which was slightly higher compared with 22% from the PCL scaffold (P 0.0027). By 24 h, the release of L. sericata maggot E/S from PCLb-PEG/PCL (32%) was slightly higher (P <0.0001) than that released from PCL (28%). L. sericata maggot E/S release increased progressively for 21 days, reaching values of 58% from (PCL) and 67% from PCL-b-PEG/PCL scaffolds. PCL-b-PEG/PCL released a statistically significantly higher percentage of L. sericata maggot E/S after 21 days compared with that released from PCL (P <0.0001). In terms of cumulative amount of protein released, ~12 μg of L. sericata maggot E/S were measured from both electrospun scaffolds after 24 h. After 21 days of release, a further 12 μg of protein was released in total from the PCL scaffolds and 14 μg from PCL-b-PEG/PCL scaffolds. Experiments carried out in triplicate, and three independent experiments (means±SD).
Discussion
The design of bioactive scaffolds is an effective strategy to stimulate and promote tissue regeneration [21] . There is a high need to develop materials that are capable of supporting cellular growth whilst releasing therapeutic molecules to modulate cellular function and promote tissue regeneration [22] .
Fibre diameter determines the pore size and porosity of electrospun scaffolds which play an important role as the structural support for cellular proliferation and infiltration [23, 24] . It has been reported that fibroblasts prefer scaffolds with a fibre diameter in the sub-micron scale as these scaffolds allow fibroblasts to penetrate into the fibres [25, 26] while electrospun fibre diameters on the nanoscale, reduces the average pore size and porosity [27, 28] . The scaffolds produced in this study are in line with the above values.
Blends of PEG-PCL polymers have been used as a strategy to modify the mechanical properties, wettability, biocompatibility, and solubility of these scaffolds in water and thus accelerate the degradability of the scaffolds [29, 30] . The mechanical properties of scaffolds designed for the treatment of skin lesions should match those of the skin itself [31] . For native skin, values of Young modulus are reported to be within the range of ~5-30 MPa [32] . The PCL and the PCL-b-PEG/PCL electrospun scaffolds presented here matched these mechanical properties. It was hypothesised that increasing the hydrophilicity of the scaffolds, by the incorporation of PEG, would also support cellular biocompatibility and increase the degradation rate of the material. The findings presented here are in agreement with studies conducted by Huan et. al 2004 [33] , who compared the degradation of three different types scaffolds (fabricated by using a 3D dispensing rapid prototyping machine) made from PCL, PCL-b-PEG and PCL-PEG-PCL over 60 weeks. PCL-b-PEG scaffolds degraded faster than PCL due to PEG-rich species releasing soluble oligomers. In this study, no significant differences were found in terms of wettability between both materials (PCL and PCL-b-PEG/PCL scaffolds) however the measurement of wettability may have been affected by the roughness of the electrospun scaffolds. We found that the PCL-b-PEG/PCL significantly improved cellular infiltration and biocompatibility compared with PCL scaffolds which is in line with findings reported by others [29, 34] . These scaffolds had the same fibre diameter and therefore we attribute these finding to differences in chemical composition due to the moisture-rich environment that PEG creates around cells adherent to the scaffolds [35] . However, this is only true at certain concentrations of PEG; at higher concentrations we observed that the scaffolds were unable to support 3T3 proliferation. It is well accepted that certain concentrations of PEG decrease protein adsorption and therefore inhibits cell attachment and protein adsorption, due to an entropic steric repulsion effect [36] .
This investigation also aimed to develop an electrospun scaffold loaded with therapeutic biomolecules in addition to supporting dermal fibroblast proliferation and infiltration into the material. For our intended application of wound healing, such a scaffold would provide structural stability to cell-growth and infiltration, as well the capacity of releasing active biomolecules. Biomolecules that have therapeutic properties, including antimicrobial, antioxidant, anti-inflammatory and mitogenic activities have been used for many years for wound healing [22] .
There are a number of examples of active dressings based on electrospun scaffolds containing growth factors, antimicrobials and other drugs (i.e antioxidants) [37, 38] .
We chose secretions from L. sericata maggot E/S that has been previously shown to enhance the migration of fibroblasts which are a pivotal in wound healing [39] . The incorporation of bioactive molecules secreted from L.
sericata maggots E/S on the surface of the electrospun fibres of PCL-PEG/PCL fibres is a novel approach for skin wound healing and it is the first time that bioactive molecules from this organism has been included within electrospun scaffolds.
The data showed that L. sericata maggot E/S could be successfully loaded onto PCL-b-PEG/PCL scaffolds but this was not significantly different with respect to loading PCL scaffolds. In addition, the data illustrated that L.
sericata maggot E/S was released in a sustainable manner from all scaffolds and to a greater extent from the PCL- The results presented here illustrated that PCL-b-PEG/PCL fibrous scaffolds supported mammalian cell adhesion, proliferation and cell infiltration within the fibres. In addition, PCL-b-PEG/PCL scaffolds were suitable for the loading, release and preservation of bioactivity of L. sericata maggot E/S. In the future, we aim to evaluate therapeutic effectiveness of the L. sericata maggot E/S released from such scaffolds on fibroblast, endothelial and keratinocyte proliferation though in vitro scratch assays. An in vivo and ex vivo model that allows the testing of the effect of L. sericata maggot E/S for a long period of time (including histological assessment) will be necessary to evaluate any long-term impact on wound healing.
Conclusions
The development of a bioactive scaffold which combines a supportive structure for mammalian cell proliferation and infiltration in addition to being a drug release platform, is a promising approach for tissue engineering applications. Herein we showed that a biocompatible PCL-PEG/PCL fibrous scaffold supported skin fibroblasts and the release of L. sericata maggot E/S which includes enzymes previously shown to modulate fibroblast motogenesis and angiogenesis. In addition, PCL-PEG/PCL scaffolds used as a platform for drug delivery provides a stable environment to preserve the bioactivity and integrity of therapeutic molecules, including proteins.
The sustained release of serine proteinases from PCL-b-PEG/PCL fibre scaffolds is proposed for potential application in wound healing. The incorporation of bioactive molecules secreted from L. sericata maggot E/S on the surface of the electrospun fibres of PCL-PEG/PCL fibres is a novel approach for skin wound healing and it is the first time that bioactive molecules of L. sericata maggot have been included within electrospun scaffolds to produce a controlled release 3D scaffold.
